BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37477764)

  • 21. Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection.
    Maurice JB; Goldin R; Hall A; Price JC; Sebastiani G; Morse CG; Prat LI; Perazzo H; Garvey L; Ingiliz P; Guaraldi G; Tsochatzis E; Lemoine M
    Clin Infect Dis; 2021 Oct; 73(7):e2184-e2193. PubMed ID: 32877569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
    Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
    Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
    [No Abstract]   [Full Text] [Related]  

  • 23. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
    Kamada Y; Nakamura T; Isobe S; Hosono K; Suama Y; Ohtakaki Y; Nauchi A; Yasuda N; Mitsuta S; Miura K; Yamamoto T; Hosono T; Yoshida A; Kawanishi I; Fukushima H; Kinoshita M; Umeda A; Kinoshita Y; Fukami K; Miyawaki T; Fujii H; Yoshida Y; Kawanaka M; Hyogo H; Morishita A; Hayashi H; Tobita H; Tomita K; Ikegami T; Takahashi H; Yoneda M; Jun DW; Sumida Y; Okanoue T; Nakajima A;
    J Gastroenterol; 2023 Feb; 58(2):79-97. PubMed ID: 36469127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
    PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.